Eigo Otsuji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eigo Otsuji has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Shiozaki
Department of Surgery, Division of Digestive Surgery, Graduate School of Medical Science Kyoto Prefectural University of Medicine Kyoto Japan
14 shared publications - Kazuma Okamoto
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
10 shared publications - Hirotaka Konishi
Division of Digestive Surgery, Department of Surgery Kyoto Prefectural University of Medicine Kyoto Japan
8 shared publications - Hitoshi Fujiwara
Kyoto Prefectural University of Medicine
8 shared publications - Shuhei Komatsu
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
8 shared publications - Daisuke Ichikawa
First Department of Surgery Faculty of Medicine University of Yamanashi Chuo Yamanashi Japan
7 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gastric Cancer
- Vol. 26 (2) , 232-246
Endoscopic Features of Background Gastritis Associated With Remnant Gastric Cancer: A Multicenter Retrospective Study
Ohashi T, et al. J Gastric Cancer. 2026 Apr;26(2):232-246. https://doi.org/10.5230/jgc.2026.26.e15
- 1 January 2026
- Published by XMLink in Journal of Gastric Cancer
- Vol. 26 (2) , 232-246
Open AccessEndoscopic Features of Background Gastritis Associated With Remnant Gastric Cancer: A Multicenter Retrospective Study
Ohashi T, et al. J Gastric Cancer. 2026 Apr;26(2):232-246. https://doi.org/10.5230/jgc.2026.26.e15
- 19 August 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (13) , 8688-8689
ASO Author Reflections: NADPH Oxidase 2 has Potential as a Therapeutic Target for Esophageal Squamous Cell Carcinoma
- 19 August 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (13) , 8688-8689
ASO Author Reflections: NADPH Oxidase 2 has Potential as a Therapeutic Target for Esophageal Squamous Cell Carcinoma
- Open Access
- 31 July 2022
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 22 (3) , 235-247
Impact of Tumor Location on the Quality of Life of Patients Undergoing Total or Proximal Gastrectomy
Fujisaki M, et al. J Gastric Cancer. 2022 Jul;22(3):235-247. https://doi.org/10.5230/jgc.2022.22.e23
- 31 July 2022
- Published by The Korean Gastric Cancer Association in Journal of Gastric Cancer
- Vol. 22 (3) , 235-247
Open AccessImpact of Tumor Location on the Quality of Life of Patients Undergoing Total or Proximal Gastrectomy
Fujisaki M, et al. J Gastric Cancer. 2022 Jul;22(3):235-247. https://doi.org/10.5230/jgc.2022.22.e23
- 16 April 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (7) , 4536-4537
ASO Author Reflections: CACNA2D1 may have a Potential as a Biomarker for Cancer Growth and as a Therapeutic Target for Gastric Cancer
- 16 April 2022
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 29 (7) , 4536-4537
ASO Author Reflections: CACNA2D1 may have a Potential as a Biomarker for Cancer Growth and as a Therapeutic Target for Gastric Cancer
- 30 June 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 124 (5) , 791-800
Oligometastasis scoring system for predicting survival of patients with colorectal liver metastasis after hepatectomy
Background: Oligometastasis, the presence of a small number of resectable metastatic tumors, usually has favorable outcomes. Here we examined whether the novel oligometastatic score (OLGS), which divides the number of colorectal liver metastases (CRLMs) by the time from colorectal resection to liver recurrence, better predicts CRLM patient survival than the commonly used clinical risk score.Methods: A total of 143 patients who underwent curative hepatectomy for CRLMs between 2007 and 2018 were analyzed. We investigated their clinical characteristics and outcomes using OLGS.Results: Of the 143 CRLM patients, 70 had synchronous CRLMs and 73 had metachronous CRLMs. Patients with metachronous CRLMs were divided into OLGS‐low (n = 59) and OLGS‐high (n = 14) subgroups. The 5‐year overall survival (OS) rates after hepatectomy differed significantly between the subgroups (p < .001). In the multivariate Cox model, a high OLGS was an independent predictor of 5‐year OS (p < .001), and the hazard ratio (HR) of the OLGS‐high group (HR = 7.171) was higher than that of the high clinical risk score group (HR = 4.337).Conclusion: The OLGS, a simple and handy scoring system, better predicts the 5‐year OS of patients with CRLMs after hepatectomy and warrants prospective validation.
- 30 June 2021
- Published by Wiley in Journal of Surgical Oncology
- Vol. 124 (5) , 791-800
Oligometastasis scoring system for predicting survival of patients with colorectal liver metastasis after hepatectomy
Background: Oligometastasis, the presence of a small number of resectable metastatic tumors, usually has favorable outcomes. Here we examined whether the novel oligometastatic score (OLGS), which divides the number of colorectal liver metastases (CRLMs) by the time from colorectal resection to liver recurrence, better predicts CRLM patient survival than the commonly used clinical risk score.Methods: A total of 143 patients who underwent curative hepatectomy for CRLMs between 2007 and 2018 were analyzed. We investigated their clinical characteristics and outcomes using OLGS.Results: Of the 143 CRLM patients, 70 had synchronous CRLMs and 73 had metachronous CRLMs. Patients with metachronous CRLMs were divided into OLGS‐low (n = 59) and OLGS‐high (n = 14) subgroups. The 5‐year overall survival (OS) rates after hepatectomy differed significantly between the subgroups (p < .001). In the multivariate Cox model, a high OLGS was an independent predictor of 5‐year OS (p < .001), and the hazard ratio (HR) of the OLGS‐high group (HR = 7.171) was higher than that of the high clinical risk score group (HR = 4.337).Conclusion: The OLGS, a simple and handy scoring system, better predicts the 5‐year OS of patients with CRLMs after hepatectomy and warrants prospective validation.
- 5 May 2021
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (5) , 2441-2449
MiR-3663-3p Inhibits the Progression of Gastric Cancer Through the CCND1 Pathway
Background/Aim: The regulation of gene expression by miRNAs plays an important role in cancer progression. Here, we investigated the role of miR-3663-3p in gastric cancer. Patients and Methods: The relationship between miR-3663-3p expression, clinicopathological features and prognosis were retrospectively analyzed in 80 gastric cancer patients. Results: miR-3663-3p expression was significantly lower in gastric cancer tissue than adjacent non-cancerous tissue (p=0.002). Recurrence free survival was significantly lower in patients with low miR-3663-3p expression (p=0.016). Low miR-3663-3p expression was also an independent predictive factor for recurrence (p=0.029). Overexpression of miR-3663-3p in gastric cancer cell lines significantly suppressed cell proliferation, migration/invasion, and induced G0/G1 arrest (p<0.01). Furthermore, overexpression of miR-3663-3p decreased Cyclin D1 mRNA and protein, and reduced the phosphorylation of Retinoblastoma (Rb) protein. Conclusion: miR-3663-3p is a clinically useful predictor of gastric cancer recurrence. It exhibits tumor suppressive features through limited entry into the cell cycle in a Cyclin D1-Rb dependent manner.
- 5 May 2021
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 41 (5) , 2441-2449
MiR-3663-3p Inhibits the Progression of Gastric Cancer Through the CCND1 Pathway
Background/Aim: The regulation of gene expression by miRNAs plays an important role in cancer progression. Here, we investigated the role of miR-3663-3p in gastric cancer. Patients and Methods: The relationship between miR-3663-3p expression, clinicopathological features and prognosis were retrospectively analyzed in 80 gastric cancer patients. Results: miR-3663-3p expression was significantly lower in gastric cancer tissue than adjacent non-cancerous tissue (p=0.002). Recurrence free survival was significantly lower in patients with low miR-3663-3p expression (p=0.016). Low miR-3663-3p expression was also an independent predictive factor for recurrence (p=0.029). Overexpression of miR-3663-3p in gastric cancer cell lines significantly suppressed cell proliferation, migration/invasion, and induced G0/G1 arrest (p<0.01). Furthermore, overexpression of miR-3663-3p decreased Cyclin D1 mRNA and protein, and reduced the phosphorylation of Retinoblastoma (Rb) protein. Conclusion: miR-3663-3p is a clinically useful predictor of gastric cancer recurrence. It exhibits tumor suppressive features through limited entry into the cell cycle in a Cyclin D1-Rb dependent manner.
- 12 March 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (11) , 6437-6438
ASO Author Reflections: Expression and Role of CFTR in Human Esophageal Squamous Cell Carcinoma
- 12 March 2021
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (11) , 6437-6438
ASO Author Reflections: Expression and Role of CFTR in Human Esophageal Squamous Cell Carcinoma
- 10 February 2021
- Published by Springer Nature
- p. 71-88
Transmediastinal Approach for Esophageal Cancer: Upper and Middle Mediastinal Dissection with Single-Port Technique
- 10 February 2021
- Published by Springer Nature
- p. 71-88
Transmediastinal Approach for Esophageal Cancer: Upper and Middle Mediastinal Dissection with Single-Port Technique
- Open Access
- 28 November 2020
- Published by Baishideng Publishing Group Inc. in Artificial Intelligence in Gastroenterology
- Vol. 1 (4) , 71-85
Artificial intelligence in gastrointestinal cancer: Recent advances and future perspectives
Artificial intelligence (AI) using machine or deep learning algorithms is attracting increasing attention because of its more accurate image recognition ability and prediction performance than human-aid analyses. The application of AI models to gastrointestinal (GI) clinical oncology has been investigated for the past decade. AI has the capacity to automatically detect and diagnose GI tumors with similar diagnostic accuracy to expert clinicians. AI may also predict malignant potential, such as tumor histology, metastasis, patient survival, resistance to cancer treatments and the molecular biology of tumors, through image analyses of radiological or pathological imaging data using complex deep learning models beyond human cognition. The introduction of AI-assisted diagnostic systems into clinical settings is expected in the near future. However, limitations associated with the evaluation of GI tumors by AI models have yet to be resolved. Recent studies on AI-assisted diagnostic models of gastric and colorectal cancers in the endoscopic, pathological, and radiological fields were herein reviewed. The limitations and future perspectives for the application of AI systems in clinical settings have also been discussed. With the establishment of a multidisciplinary team containing AI experts in each medical institution and prospective studies, AI-assisted medical systems will become a promising tool for GI cancer.
- 28 November 2020
- Published by Baishideng Publishing Group Inc. in Artificial Intelligence in Gastroenterology
- Vol. 1 (4) , 71-85
Open AccessArtificial intelligence in gastrointestinal cancer: Recent advances and future perspectives
Artificial intelligence (AI) using machine or deep learning algorithms is attracting increasing attention because of its more accurate image recognition ability and prediction performance than human-aid analyses. The application of AI models to gastrointestinal (GI) clinical oncology has been investigated for the past decade. AI has the capacity to automatically detect and diagnose GI tumors with similar diagnostic accuracy to expert clinicians. AI may also predict malignant potential, such as tumor histology, metastasis, patient survival, resistance to cancer treatments and the molecular biology of tumors, through image analyses of radiological or pathological imaging data using complex deep learning models beyond human cognition. The introduction of AI-assisted diagnostic systems into clinical settings is expected in the near future. However, limitations associated with the evaluation of GI tumors by AI models have yet to be resolved. Recent studies on AI-assisted diagnostic models of gastric and colorectal cancers in the endoscopic, pathological, and radiological fields were herein reviewed. The limitations and future perspectives for the application of AI systems in clinical settings have also been discussed. With the establishment of a multidisciplinary team containing AI experts in each medical institution and prospective studies, AI-assisted medical systems will become a promising tool for GI cancer.